AEZS: Aeterna Zentaris Growth-Adjusted Market Cap to Net Income

Aeterna Zentaris (AEZS) revenues rely on licensing payments and new formulas. The PEG ratio undervaluation reflects the current market position, where 0.00 serves as the final level marker. The company develops diagnostics for endocrine pathologies tailored for specialized clinics. Macrilen is considered a competitive advantage as the only non-injection growth hormone deficiency test, ensuring safety for children.

An investor determines an asset's margin of safety through the ratio of the P/E coefficient to earnings growth rates, where a value below one signals a fundamental undervaluation relative to earnings dynamics. Due to Macrilen's monopoly position in growth hormone deficiency diagnostics, the growth company undervaluation metric on GURU.Markets confirms the potential of Aeterna Zentaris (AEZS) as a high-yield asset with low demand elasticity.